Cornerstone Capital Management Holdings’s Supernus Pharmaceuticals SUPN Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$4.59M	Buy	115,100 +6,100	+6%	+$241K	0.03%	493
2017 Q3	$4.36M	Buy	109,000 +59,800	+122%	+$2.59M	0.03%	475
2017 Q2	$2.12M	Sell	49,200 -118,600	-71%	-$4.22M	0.02%	710
2017 Q1	$5.25M	Sell	167,800 -8,900	-5%	-$239K	0.04%	448
2016 Q4	$4.46M	Sell	176,700 -1,850	-1%	-$41.3K	0.03%	509
2016 Q3	$4.41M	Buy	178,550 +80,650	+82%	+$1.83M	0.03%	503
2016 Q2	$1.99M	Sell	97,900 -154,700	-61%	-$2.74M	0.02%	727
2016 Q1	$3.85M	Buy	252,600 +129,000	+104%	+$1.68M	0.03%	540
2015 Q4	$1.66M	Buy	123,600 +16,300	+15%	+$252K	0.01%	784
2015 Q3	$1.5M	Sell	107,300 -3,200	-3%	-$59.5K	0.01%	796
2015 Q2	$1.88M	Buy	+110,500	New	+$1.57M	0.02%	734
2015 Q1	–	Sell	-23,800	Closed	-$198K	–	1425
2014 Q4	$198K	Buy	+23,800	New	+$200K	﹤0.01%	1092

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Cornerstone Capital Management Holdings's SUPN Position: Q4 2017 in Review

Cornerstone Capital Management Holdings increased its Supernus Pharmaceuticals (SUPN) stake by 5.6% in Q4 2017, buying an estimated $241K and bringing the position to 115,100 shares worth $4.59M. The position accounts for 0.03% of the portfolio, ranked #493.

Cornerstone Capital Management Holdings first reported a position in SUPN in Q4 2014 and has held it in 12 quarters since. The position peaked at $5.25M in Q1 2017. 297 funds tracked by Wall St. Rank hold SUPN as of Q4 2017.

Cornerstone Capital Management Holdings held 115,100 shares of Supernus Pharmaceuticals worth $4.59M as of Q4 2017.
Cornerstone Capital Management Holdings bought 6,100 Supernus Pharmaceuticals shares in Q4 2017, an estimated $241K.
Supernus Pharmaceuticals made up 0.03% of Cornerstone Capital Management Holdings's portfolio in Q4 2017, its #493 holding.
Cornerstone Capital Management Holdings first reported a position in Supernus Pharmaceuticals in Q4 2014 and has held it in 12 quarters since.
Cornerstone Capital Management Holdings's Supernus Pharmaceuticals position peaked at $5.25M in Q1 2017.
297 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2017.

Based on Cornerstone Capital Management Holdings's 13F filing for Q4 2017, filed 14 Feb 2018.